Erik Regidor
Research Subjects
Erik Regidor has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Ortiz‐Vigón
Etiology and Therapy of Periodontal and Periimplant Diseases (ETEP) Research Group, Faculty of Odontology Complutense University Madrid Spain
15 shared publications - Jan Derks
Department of Periodontology Institute of Odontology, The Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden
7 shared publications - Carlotta Dionigi
Department of Periodontology, Institute of Odontology The Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden
5 shared publications Alberto Ortiz‐Vigón
Periodontal and Peri‐Implant Related Diseases and Therapies Arrow Development SL Bilbao Spain
4 shared publications- Cristiano Tomasi
Department of Periodontology Institute of Odontology, The Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden
4 shared publications - Adrián Guerrero
Private practice Clínica Guerrero Marbella Spain
3 shared publications
Latest Publications
- 28 June 2026
- Published by Wiley in Clinical Oral Implants Research
- Vol. 37 (9) , 1109-1117
Adjunctive Electrolytic Implant Surface Decontamination in the Reconstructive Surgical Treatment of Peri‐Implantitis—A Randomized Clinical Trial
Objectives: The aim of this study was to evaluate the adjunctive effect of electrolytic cleaning in the surgical treatment of peri‐implantitis. Materials and Methods: A total of 40 patients (44 implants) with peri‐implantitis‐associated intra‐bony defects were included in this single‐center randomized controlled trial. Surgical decontamination of implant surfaces was initiated by use of a rotating titanium brush. Following random allocation, adjunctive electrolytic cleaning was performed in the test group. Xenogeneic bone substitute and a resorbable collagen membrane were then used in both groups. Clinical parameters including probing pocket depth (PPD), bleeding/suppuration on probing, buccal mucosal recession (REC), and keratinized mucosa were assessed at 6 and 12 months. Radiographic marginal bone levels (MBL) and patient‐reported outcomes (PROs) were evaluated at 12 months. The primary outcome was a composite measure including implant survival, complete absence of BoP/SoP, PPD ≤ 5 mm and REC ≤ 1 mm at 12 months. Results: At 12 months, no implants were lost. The composite outcome was complete at 27.3% of control and 40.0% of test implants ( p = 0.41 ). Mean PPD reductions were 4.5 ± 2.6 mm (control) and 3.8 ± 2.3 mm (test), while MBL gains were 1.9 ± 2.4 mm and 2.1 ± 2.0 mm, respectively. No significant intergroup differences were observed for any clinical, radiographic or PROs. Post‐surgical complications occurred in the test group. Conclusions: Clinical, radiographic and patient‐reported outcomes of surgical therapy of peri‐implantitis were favorable at 12 months. The adjunctive use of electrolytic cleaning provided no added benefit over the use of a rotating titanium brush alone. Trial Registration: ISRCTN17197337 (ISRCTN)
- 28 June 2026
- Published by Wiley in Clinical Oral Implants Research
- Vol. 37 (9) , 1109-1117
Adjunctive Electrolytic Implant Surface Decontamination in the Reconstructive Surgical Treatment of Peri‐Implantitis—A Randomized Clinical Trial
Objectives: The aim of this study was to evaluate the adjunctive effect of electrolytic cleaning in the surgical treatment of peri‐implantitis. Materials and Methods: A total of 40 patients (44 implants) with peri‐implantitis‐associated intra‐bony defects were included in this single‐center randomized controlled trial. Surgical decontamination of implant surfaces was initiated by use of a rotating titanium brush. Following random allocation, adjunctive electrolytic cleaning was performed in the test group. Xenogeneic bone substitute and a resorbable collagen membrane were then used in both groups. Clinical parameters including probing pocket depth (PPD), bleeding/suppuration on probing, buccal mucosal recession (REC), and keratinized mucosa were assessed at 6 and 12 months. Radiographic marginal bone levels (MBL) and patient‐reported outcomes (PROs) were evaluated at 12 months. The primary outcome was a composite measure including implant survival, complete absence of BoP/SoP, PPD ≤ 5 mm and REC ≤ 1 mm at 12 months. Results: At 12 months, no implants were lost. The composite outcome was complete at 27.3% of control and 40.0% of test implants ( p = 0.41 ). Mean PPD reductions were 4.5 ± 2.6 mm (control) and 3.8 ± 2.3 mm (test), while MBL gains were 1.9 ± 2.4 mm and 2.1 ± 2.0 mm, respectively. No significant intergroup differences were observed for any clinical, radiographic or PROs. Post‐surgical complications occurred in the test group. Conclusions: Clinical, radiographic and patient‐reported outcomes of surgical therapy of peri‐implantitis were favorable at 12 months. The adjunctive use of electrolytic cleaning provided no added benefit over the use of a rotating titanium brush alone. Trial Registration: ISRCTN17197337 (ISRCTN)
- 3 November 2025
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 53 (2) , 268-285
The Use of a Resorbable Membrane as an Adjunct to a Xenogeneic Bone Replacement Graft in the Reconstructive Surgical Therapy of Peri‐Implantitis: 3‐Year Results of a Randomised Clinical Trial
Aim: To evaluate the effect of the adjunctive use of a resorbable collagen membrane in the reconstructive surgical therapy of peri‐implantitis. Material and Methods: Forty‐three patients (43 implants) diagnosed with peri‐implantitis underwent surgical treatment using a reconstructive approach, which included a bone substitute material with (test) or without (control) a resorbable collagen membrane. Supportive peri‐implant treatment was administered biannually during the 3‐year follow‐up period. Clinical outcomes, such as probing pocket depth (PPD), bleeding on probing (BOP), suppuration on probing (SOP), marginal mucosal level (REC) and keratinised mucosa width (KM), were recorded at baseline, as well as at 6, 12 and 36 months. Radiographic marginal bone levels (MBLs) and patient‐reported outcomes (PROs) were also evaluated. The primary outcome was a composite measure consisting of PPD ≤ 5 mm, absence of BOP/SOP and buccal REC of ≤ 1 mm. A second composite outcome, termed ‘disease resolution’, was also assessed, defined as PPD ≤ 5 mm, BOP at ≤ 1 site and complete absence of SOP. Results: Out of the 43 participants, 8 were lost to follow‐up, 2 experienced implant loss and 1 was surgically re‐treated. At 3 years, the composite outcome was achieved for 25.0% of implants (test: 17.6%; control: 27.8%), while disease resolution was achieved for 31.2% (test: 29.4%; control: 27.8%). Overall, PPD and BOP were reduced by 3.6 ± 3.2 mm and 37.5% ± 42.1%, respectively. Changes in buccal REC and KM were 0.5 ± 1.3 and 1.1 ± 1.5 mm, respectively. An overall bone gain (MBL change) of 1.0 ± 2.2 mm was observed. PROs were favourable. No statistically significant differences were observed between groups. Conclusion: Adding a collagen membrane to a bone substitute material in the surgical treatment of peri‐implantitis did not yield any benefits regarding clinical, radiographic or patient‐reported outcomes. Trial Registration: ISRCTN67095066 ( https://www.isrctn.com/ISRCTN67095066 )
- 3 November 2025
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 53 (2) , 268-285
The Use of a Resorbable Membrane as an Adjunct to a Xenogeneic Bone Replacement Graft in the Reconstructive Surgical Therapy of Peri‐Implantitis: 3‐Year Results of a Randomised Clinical Trial
Aim: To evaluate the effect of the adjunctive use of a resorbable collagen membrane in the reconstructive surgical therapy of peri‐implantitis. Material and Methods: Forty‐three patients (43 implants) diagnosed with peri‐implantitis underwent surgical treatment using a reconstructive approach, which included a bone substitute material with (test) or without (control) a resorbable collagen membrane. Supportive peri‐implant treatment was administered biannually during the 3‐year follow‐up period. Clinical outcomes, such as probing pocket depth (PPD), bleeding on probing (BOP), suppuration on probing (SOP), marginal mucosal level (REC) and keratinised mucosa width (KM), were recorded at baseline, as well as at 6, 12 and 36 months. Radiographic marginal bone levels (MBLs) and patient‐reported outcomes (PROs) were also evaluated. The primary outcome was a composite measure consisting of PPD ≤ 5 mm, absence of BOP/SOP and buccal REC of ≤ 1 mm. A second composite outcome, termed ‘disease resolution’, was also assessed, defined as PPD ≤ 5 mm, BOP at ≤ 1 site and complete absence of SOP. Results: Out of the 43 participants, 8 were lost to follow‐up, 2 experienced implant loss and 1 was surgically re‐treated. At 3 years, the composite outcome was achieved for 25.0% of implants (test: 17.6%; control: 27.8%), while disease resolution was achieved for 31.2% (test: 29.4%; control: 27.8%). Overall, PPD and BOP were reduced by 3.6 ± 3.2 mm and 37.5% ± 42.1%, respectively. Changes in buccal REC and KM were 0.5 ± 1.3 and 1.1 ± 1.5 mm, respectively. An overall bone gain (MBL change) of 1.0 ± 2.2 mm was observed. PROs were favourable. No statistically significant differences were observed between groups. Conclusion: Adding a collagen membrane to a bone substitute material in the surgical treatment of peri‐implantitis did not yield any benefits regarding clinical, radiographic or patient‐reported outcomes. Trial Registration: ISRCTN67095066 ( https://www.isrctn.com/ISRCTN67095066 )
- Open Access
- 20 June 2025
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (9) , 1159-1171
Surgical Treatment of Peri‐Implantitis Combined With Keratinized Mucosa Augmentation: Results of a Dual‐Center 3‐Year RCT
Aim: To evaluate the medium‐term efficacy of using a xenogeneic collagen matrix to augment the width of the peri‐implant keratinized mucosa (PIKM) as an adjunct to the surgical treatment of peri‐implantitis.Material and Methods: In this 36‐month parallel‐arm randomized controlled clinical trial, patients with peri‐implantitis were randomly assigned to a combined protocol of resective peri‐implantitis surgery and a PIKM augmentation procedure, either with an autologous free gingival graft (FGG) or a collagen matrix (CM). Primary outcomes were the increase in the width of PIKM and probing pocket depth (PPD) reduction at 36 months. As secondary outcomes, radiographic and patient‐reported outcomes were assessed.Results: Forty‐one patients (20 in the CM group and 21 in the FGG group) completed the three‐year follow‐up. PIKM increased in both groups, but the increase was significantly higher in the APF (apically positioned flap) + FGG group compared to the APF + CM group [2.0 (95% CI: 1.3, 2.7) mm in the FGG group compared to 1.0 (95% CI: 0.5, 1.5) mm in the CM group; p = 0.048]. PPDs were reduced by 1.5 mm (95% CI: 1.1, 1.9) and 1.4 mm (95% CI: 0.6, 2.2), respectively. Disease resolution (maximum one site with bleeding on probing, no suppuration, no further bone loss > 0.5 mm, and PD ≤ 5 mm) was 47.6% in the FGG group and 35.0% in the CM group.Conclusion: Tested surgical modalities resulted in similar improvements in the clinical parameters. Both FGG and CM increased the PIKM, but PIKM was greater at the 36‐month examination in the FGG group.
- 20 June 2025
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (9) , 1159-1171
Open AccessSurgical Treatment of Peri‐Implantitis Combined With Keratinized Mucosa Augmentation: Results of a Dual‐Center 3‐Year RCT
Aim: To evaluate the medium‐term efficacy of using a xenogeneic collagen matrix to augment the width of the peri‐implant keratinized mucosa (PIKM) as an adjunct to the surgical treatment of peri‐implantitis.Material and Methods: In this 36‐month parallel‐arm randomized controlled clinical trial, patients with peri‐implantitis were randomly assigned to a combined protocol of resective peri‐implantitis surgery and a PIKM augmentation procedure, either with an autologous free gingival graft (FGG) or a collagen matrix (CM). Primary outcomes were the increase in the width of PIKM and probing pocket depth (PPD) reduction at 36 months. As secondary outcomes, radiographic and patient‐reported outcomes were assessed.Results: Forty‐one patients (20 in the CM group and 21 in the FGG group) completed the three‐year follow‐up. PIKM increased in both groups, but the increase was significantly higher in the APF (apically positioned flap) + FGG group compared to the APF + CM group [2.0 (95% CI: 1.3, 2.7) mm in the FGG group compared to 1.0 (95% CI: 0.5, 1.5) mm in the CM group; p = 0.048]. PPDs were reduced by 1.5 mm (95% CI: 1.1, 1.9) and 1.4 mm (95% CI: 0.6, 2.2), respectively. Disease resolution (maximum one site with bleeding on probing, no suppuration, no further bone loss > 0.5 mm, and PD ≤ 5 mm) was 47.6% in the FGG group and 35.0% in the CM group.Conclusion: Tested surgical modalities resulted in similar improvements in the clinical parameters. Both FGG and CM increased the PIKM, but PIKM was greater at the 36‐month examination in the FGG group.
- 26 March 2025
- Published by Wiley in Journal of Periodontal Research
- Vol. 61 (1) , 54-65
Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial
Aims: To evaluate the adjunctive effect of enamel matrix derivative (EMD) in the reconstructive surgical therapy of peri‐implantitis. Methods: Forty subjects (44 implants) affected by peri‐implantitis (PPD ≥ 5 mm, positive BOP/SOP, intraosseous defect with a depth of ≥ 3 mm and width of ≤ 4 mm) were randomly allocated to one of two surgical protocols: control (access flap + bone graft + resorbable membrane) or test (access flap + bone graft + resorbable membrane + EMD). Clinical outcomes (PPD, BOP, SOP, buccal REC, and buccal KM) were assessed at baseline, 6 and 12 months after surgery. Radiographic marginal bone levels (MBL) and patient‐reported outcomes (PROs) were recorded at baseline and at 12 months. Post‐operative complications and Early Healing Index (EHI) scores were recorded at 2 weeks. The primary outcome was PPD change. Two composite outcomes (CO) were assessed: CO1 was defined as “implant not lost, PPD ≤ 5 mm, REC ≤ 1 mm and complete absence of BOP/SOP”; CO2 defined as CO1 but allowing for 1 site with BOP. Results: Four patients (four implants) were lost to follow‐up. At 12 months, no implants were lost, 73% of implants presented with PPD ≤ 5 mm (control: 65.2%; test: 81.0%; p = 0.316) and PPD reduction amounted to 4.0 ± 1.7 and 4.3 ± 2.4 mm in control and test groups, respectively ( p = 0.105). No significant differences in terms of clinical, radiographic, composite and PROs were observed between groups. No significant differences in EHI scores were found at 2 weeks between groups. Conclusion: This study failed to demonstrate any benefit of the adjunctive use of EMD in the reconstructive surgical therapy of peri‐implantitis. Trial Registration: ISRCTN18159776 ( https://doi.org/10.1186/ISRCTN18159776 )
- 26 March 2025
- Published by Wiley in Journal of Periodontal Research
- Vol. 61 (1) , 54-65
Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial
Aims: To evaluate the adjunctive effect of enamel matrix derivative (EMD) in the reconstructive surgical therapy of peri‐implantitis. Methods: Forty subjects (44 implants) affected by peri‐implantitis (PPD ≥ 5 mm, positive BOP/SOP, intraosseous defect with a depth of ≥ 3 mm and width of ≤ 4 mm) were randomly allocated to one of two surgical protocols: control (access flap + bone graft + resorbable membrane) or test (access flap + bone graft + resorbable membrane + EMD). Clinical outcomes (PPD, BOP, SOP, buccal REC, and buccal KM) were assessed at baseline, 6 and 12 months after surgery. Radiographic marginal bone levels (MBL) and patient‐reported outcomes (PROs) were recorded at baseline and at 12 months. Post‐operative complications and Early Healing Index (EHI) scores were recorded at 2 weeks. The primary outcome was PPD change. Two composite outcomes (CO) were assessed: CO1 was defined as “implant not lost, PPD ≤ 5 mm, REC ≤ 1 mm and complete absence of BOP/SOP”; CO2 defined as CO1 but allowing for 1 site with BOP. Results: Four patients (four implants) were lost to follow‐up. At 12 months, no implants were lost, 73% of implants presented with PPD ≤ 5 mm (control: 65.2%; test: 81.0%; p = 0.316) and PPD reduction amounted to 4.0 ± 1.7 and 4.3 ± 2.4 mm in control and test groups, respectively ( p = 0.105). No significant differences in terms of clinical, radiographic, composite and PROs were observed between groups. No significant differences in EHI scores were found at 2 weeks between groups. Conclusion: This study failed to demonstrate any benefit of the adjunctive use of EMD in the reconstructive surgical therapy of peri‐implantitis. Trial Registration: ISRCTN18159776 ( https://doi.org/10.1186/ISRCTN18159776 )
- Open Access
- 20 December 2024
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (4) , 436-448
Bone Substitute Material in the Surgical Therapy of Peri‐Implantitis—3‐Year Outcomes of a Randomized Controlled Trial
Objective: To evaluate the potential mid‐term benefit of the use of a bone substitute material in the reconstructive surgical treatment of peri‐implantitis.Methods: A total of 120 subjects (127 implants) affected by peri‐implantitis were followed over 3 years in a multicenter randomized clinical trial. Participants had been randomized to either control (access flap surgery) or test group (access flap surgery and bone substitute material). Clinical, radiographic, and patient‐reported outcomes were assessed. The primary outcome was a composite measure including probing pocket depth ≤ 5 mm, absence of bleeding and suppuration on probing, soft tissue recession ≤ 1 mm, and implant neither reoperated nor lost. In an additional outcome (disease resolution), we allowed for one bleeding site and did not consider recession.Results: While 14 implants (11%) were lost and a second surgical intervention had been performed at 3 implants (2.4%), pronounced improvements of clinical parameters were noted at remaining implants in both treatment groups at the 3‐year follow‐up. This was illustrated by a 3.2–3.5 mm reduction in probing pocket depth and a marginal bone level gain of 1.1–1.3 mm. The primary composite outcome, however, was only achieved at 14% of implants. The second composite outcome defining disease resolution was accomplished at 39% of implants. Patient‐reported outcomes were generally favorable.Conclusion: At 3 years, the use of a bone substitute material in the surgical therapy of peri‐implantitis did not result in a clear benefit over access flap surgery alone.Trial Registration: ClinicalTrials.gov identifier: NCT0307706
- 20 December 2024
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (4) , 436-448
Open AccessBone Substitute Material in the Surgical Therapy of Peri‐Implantitis—3‐Year Outcomes of a Randomized Controlled Trial
Objective: To evaluate the potential mid‐term benefit of the use of a bone substitute material in the reconstructive surgical treatment of peri‐implantitis.Methods: A total of 120 subjects (127 implants) affected by peri‐implantitis were followed over 3 years in a multicenter randomized clinical trial. Participants had been randomized to either control (access flap surgery) or test group (access flap surgery and bone substitute material). Clinical, radiographic, and patient‐reported outcomes were assessed. The primary outcome was a composite measure including probing pocket depth ≤ 5 mm, absence of bleeding and suppuration on probing, soft tissue recession ≤ 1 mm, and implant neither reoperated nor lost. In an additional outcome (disease resolution), we allowed for one bleeding site and did not consider recession.Results: While 14 implants (11%) were lost and a second surgical intervention had been performed at 3 implants (2.4%), pronounced improvements of clinical parameters were noted at remaining implants in both treatment groups at the 3‐year follow‐up. This was illustrated by a 3.2–3.5 mm reduction in probing pocket depth and a marginal bone level gain of 1.1–1.3 mm. The primary composite outcome, however, was only achieved at 14% of implants. The second composite outcome defining disease resolution was accomplished at 39% of implants. Patient‐reported outcomes were generally favorable.Conclusion: At 3 years, the use of a bone substitute material in the surgical therapy of peri‐implantitis did not result in a clear benefit over access flap surgery alone.Trial Registration: ClinicalTrials.gov identifier: NCT0307706
- Open Access
- 21 August 2024
- Published by Springer Nature
Influence of tissue graft substitute in the treatment of gingival recessions
- 21 August 2024
- Published by Springer Nature
Open AccessInfluence of tissue graft substitute in the treatment of gingival recessions
- Open Access
- 21 December 2023
- Published by Springer Nature
Treatment of peri-implantitis with allografts and enamel proteins
- 21 December 2023
- Published by Springer Nature
Open AccessTreatment of peri-implantitis with allografts and enamel proteins
- Open Access
- 28 November 2023
- Published by Springer Nature
Refining bone structure for gum defects around teeth
- 28 November 2023
- Published by Springer Nature
Open AccessRefining bone structure for gum defects around teeth
- Open Access
- 14 November 2023
- Published by Springer Nature
Accuracy of digital impressions for dental implant crowns
- 14 November 2023
- Published by Springer Nature
Open AccessAccuracy of digital impressions for dental implant crowns
- Open Access
- 14 November 2023
- Published by Springer Nature
Apical access for treatment of peri-implantitis
- 14 November 2023
- Published by Springer Nature
Open AccessApical access for treatment of peri-implantitis